A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1005 | Th1002 | Cetuximab | Heavy chain:QVQLKQSG Full view | 243 | IIIc | Cancer | Erbitux | ImClone Systems Inc | Sterile, clear, colorless liquid of pH 7.0-7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates | Intravenous infusion | Antineoplastic Agents | Epidermal growth factor receptor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1025 | Th1004 | Denileukin diftitox | MGADDVVDSSKSFVMENFSS Full view | 255 | IIb | Cancer | Ontak | Seragen Inc | Sterile, white, preservative-free, lyophilized powder. | Intravenous(IV) administration | Antineoplastic Agents | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Cytokine receptor common subunit gamma |
| 1038 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Eligard | Atrix Labs/QLT In | Suspension | Subcutaneous Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1039 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Enantone | Takeda | Solution | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1040 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Leuplin | Takeda | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1041 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | LeuProMaxx | Baxter/Teva | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1042 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Leupromer | N.A. | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1043 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Lupron | Abbott/TAP Pharmaceuticals | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1044 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Lutrate | N.A. | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1045 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Memryte | Curaxis | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1046 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Prostap 3 | Takeda UK Limited | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1047 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Prostap SR | Takeda UK Limited | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1048 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Viadur | Bayer AG | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1142 | Th1020 | Asparaginase | QMSLQQELRYIEALSAIVET Full view | 255 | Ic | Cancer | Elspar | Merck & Co. Inc | Lyophilized plug or powder | Intravenous or Intramuscular. Intravenous method dose has higher risk of allergic reaction, so often a test dose is given first. | Antineoplastic Agents | L-asparagine |
| 1145 | Th1021 | Thyrotropin Alfa | Alpha chain:APDVQDC< Full view | 204 | IV | Cancer | Thyrogen | Genzyme Inc | Lyophilized powder | Intramuscular preferably the buttocks | Diagnostic Agents | Thyrotropin receptor |
| 1242 | Th1033 | Oprelvekin | GPPPGPPRVSPDPRAELDST Full view | 177 | Ib | Cancer/Haemetological | Neumega | Genetics Institute Inc | Sterile, lyophilized powder | Subcutaneous injection | Coagulants and Thrombotic Agents, Anti-neoplastic agents | Interleukin-11 receptor subunit alpha |
| 1246 | Th1034 | Palifermin | SYDYMEGGDIRVRRLFCRTQ Full view | 140 | Ib | Cancer | Kepivance | Amgen Inc | Sterile, lyophilized powder | Intravenous infusion | Anti-Mucositis Agents | Fibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein |
| 1257 | Th1036 | Aldesleukin | MAPTSSSTKKTQLQLEHLLL Full view | 134 | Ib | Cancer/Infectious | Proleukin | Chiron Corp | Sterile, white to off-white, lyophilized cake | Intravenous administration | Antineoplastic Agents, Anti-HIV agents | Interleukin-2 receptor subunit beta,Interleukin-2 receptor subunit alpha,Cytokine receptor common subunit gamma |
| 1337 | Th1048 | Pegaspargase | MEFFKKTALAALVMGFSGAA Full view | 255 | Ic | Cancer | Oncaspar | Enzon Inc | Solution | Intravenous or Intramuscular administration | Antineoplastic Agents | L-asparagine |
| 1341 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Avonex | Biogen Inc | Lyophilized powder vial, Sterile liquid as single used prefilled syringe and also available as single use prefilled autoinjector. | Intramuscular Injection | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1342 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Betaferon | Bayer | Powder and solvent that are made upto make solution. | Subcutaneous Injection | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1343 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Betaseron | Merck | Sterile, white to off-white powder | Subcutaneous Injection | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1344 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Blastoferon | Sidus | N.A. | N.A. | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1345 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Extavia | Novartis | Sterile, white to off-white powder | Subcutaneous Injection | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1346 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Rebif | Merck | Sterile solution in a prefilled syringe or REBIF Rebidose autoinjector | Subcutaneous Injection | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1385 | Th1061 | Trastuzumab | Light chain 1: DIQMT Full view | 1364 | IIa | Cancer | Herceptin | Genentech | Sterile, white to pale yellow, preservative-free lyophilized powder |  Intravenous administration | Antineoplastic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
| 1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
| 1406 | Th1066 | Ibritumomab | Heavy Chain: QAYLQQS Full view | 652 | IIb | Cancer | Zevalin | Spectrum Pharmaceuticals | Clear, colorless, sterile, pyrogen-free, preservative-free solution that may contain translucent particles. | Intravenous infusion | N.A. | Digoxin |
| 1412 | Th1068 | Tositumomab | Heavy Chain 1: QAYLQ Full view | 1351 | IIb | Cancer | Bexxar | Galaxo Smith Kline | Sterile, pyrogen-free, clear to opalescent, colorless to slightly yellow, preservative-free solution | Intravenous(IV) administration | N.A. | Bacterial outer membrane,Lipoteichoic acid synthesis |
| 1431 | Th1073 | Alemtuzumab | Heavy Chain 1: QVQLQ Full view | 2839 | IIa | Cancer | CAMPATH | Genzyme Corporation | Sterile, clear, colorless, isotonic solution (pH 6.8-7.4) | Intravenous infusion | N.A. | N.A. |
| 1432 | Th1073 | Alemtuzumab | Heavy Chain 1: QVQLQ Full view | 2389 | IIa | Cancer | LEMTRADA | Genzyme Corporation | LEMTRADA is a sterile, clear and colorless to slightly yellow, solution (pH 7.2±0.2) for infusion. | Intravenous infusion | NA | NA |
| 1435 | Th1075 | Capromab | N.A. Full view | 0 | IV | Cancer | ProstaScint | Jazz Pharmaceuticals, Inc. | Sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. | Intravenous injection | Indicators, Reagents and Diagnostic Agents | CAMPATH-1 antigen,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1470 | Th1092 | Arcitumomab | Heavy chain 1EVKLVES Full view | 1310 | IIb | Cancer | CEA-Scan | N.A. | N.A. | N.A. | Diagnostic Agents | Vascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Carcinoembryonic antigen-related cell adhesion molecule 1 |
| 1474 | Th1094 | Panitumumab | N.A. Full view | 0 | IIa | Cancer | Vectibix | Amgen Inc | Sterile, colorless, pH 5.6 to 6.0 liquid for intravenous (IV) infusion, which may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates | N.A. | N.A. | Epidermal growth factor receptor |
| 1533 | Th1112 | Natural Alpha Interferon Or Multiferon | Inteferon alpha-1: | 997 | IIa | Cancer/Infectious | Intron/ Roferon-A | N.A. | N.A. | Subcutaneous injection, Intravenous injection, Intramuscular injection | N.A. | N.A. |
| 1548 | Th1117 | Ipilimumab | Heavy chain: QVQLVES Full view | 663 | IIIc | Cancer | YERVOY | Bristol-Myers Squibb | Sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution | N.A. | Antineoplastic Agents and Monoclonal antibodies | Cytotoxic T-lymphocyte protein 4 |
| 1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
| 1600 | Th1127 | Buserelin | N.A. Full view | 0 | IIIc | Cancer/Hormonal | Suprecur (Nasal Spray Solution) | Sanofi-Aventis | 150 micrograms Nasal Spray Solution | Nasal spray | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1601 | Th1127 | Buserelin | pGlu-His-Trp-Ser-Tyr Full view | 9 | IIIc | Cancer/Hormonal | Suprecur (injection) | Sanofi-Aventis | 1mg/ml Injection | Subcutaneous injection | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1604 | Th1130 | Brentuximab Vedotin | Heavy chain:QIQLQQSG Full view | 664 | IIb | Cancer | Adcetris | Seattle Genetics | Sterile, white to off-white, preservative-free lyophilized cake or powder in single-use vials. | Intravenous infusion | N.A. | Tumor necrosis factor receptor superfamily member 8 |
| 1615 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Eylea | Regeneron Pharmaceuticals | Sterile, clear, and colorless to pale yellow solution. | Intravitreal injection | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
| 1616 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Zaltrap | Sanofi and Regeneron Pharmaceuticals, Inc. | Sterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution. | Intravenous infusion | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
| 1635 | Th1141 | Epoetin Zeta | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Cancer | Retacrit | Norbitec | solution for injection | N.A. | N.A. | Erythropoietin receptor |
| 1636 | Th1142 | Obinutuzumab | N.A. Full view | 0 | IIb | Cancer | Gazyva | Genentech | Sterile, clear, colorless to slightly brown, preservative free liquid concentrate | Intravenous infusion | Antineoplastic Agents | B-lymphocyte antigen CD20 |
| 1671 | Th1159 | Gemtuzumab ozogamicin | Light Chain 1: QIVLT Full view | 459 | IIb | Cancer | Mylotarg | Wyeth pharmaceuticals inc | Sterile, white, preservative-free lyophilized powder | Intravenous infusion | Antineoplastic agents and Immunotoxins | Myeloid cell surface antigen CD33, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1682 | Th1163 | Ancestim | NA Full view | 0 | Ib | Cancer | Stemgen | Biovitrum Ab (publ) | NA | Subcutaneous | NA | NA |
| 1703 | Th1167 | Atezolizumab | NA Full view | 0 | IIa | Cancer | Tecentriq | NA | NA | NA | NA | NA |
| 1708 | Th1170 | Blinatumomab | DIQLTQSPASLAVSLGQRAT Full view | 504 | IIIc | Cancer/Genetic | Blincyto | AMGEN | Lyophilized Powder for intravenous administration | Intravenous | Antineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents | B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain |
| 1724 | Th1174 | Daratumumab | NA Full view | 0 | IIIc | Cancer | Darzalex | Janssen Biotech, Inc. | Solution, concentrate | Intravenous | Antineoplastic Agents | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
| 1738 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | NA | NA | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | SLAM family member 7 |